In a groundbreaking achievement, TGH-Onco Life Cancer Centre has successfully treated two patients— a 70-year-old man with lung carcinoma and a 62-year-old man with prostate cancer—using the advanced Radixact System with Artificial Intelligence (AI)-based Synchrony Automatic, Real-time Motion Synchronization Technology. This marks the first time such technology has been employed for cancer treatment in Maharashtra. Both patients have recovered well following this innovative approach. Present at the press conference were Dr. Abhishek Purkayastha, Dr. Jyoti Mehta, Dr. Santosh Sahu, Mr. Sachin Deshmukh, patient Mr. Anantrao Raikar, and his son.

Mr. Anantrao Raikar, a 70-year-old resident of Talegaon, Pune, experienced severe breathlessness that hindered his daily activities. Diagnosed with lung carcinoma following a CT and whole-body PET scan, he initially received palliative chemotherapy and targeted therapy. However, disease progression was indicated by a subsequent PET scan.

Similarly, 62-year-old Nanasao Ingawale from Solapur presented with lower urinary tract symptoms and was diagnosed with prostate cancer, a leading cancer among Indian men. Both patients were deemed suitable for the AI-based Synchrony approach for successful outcomes.

Innovative Treatment Approach

Dr. Abhishek Purkayastha, Consultant, Dept of Tomotherapy and Radiation Oncology at TGH Onco-Life Cancer Centre, explained the benefits of the Radixact System with AI-based Synchrony Technology. This system offers a precise and safer option to treat highly mobile cancers, including lung, liver, gastrointestinal, and prostate cancers. The technology uses an X-ray panel and detector system, tracking tumor locations in real-time with Synchrony Respiratory Camera Array. Treatment sessions last 10 to 15 minutes, allowing the radiation beam to adjust according to the tumor's movement, improving accuracy and minimizing damage to healthy tissue.

Mr. Anantrao Raikar underwent treatment with normal breathing, avoiding the need for breath-holding or abdominal compression, ensuring maximum comfort and an improved quality of life. He tolerated the treatment without acute adverse effects and is now clinically stable. Dr. Purkayastha emphasized the importance of timely intervention to prevent further disease progression.

Dr. Jyoti Mehta, MD Radiation and Clinical Oncologist, highlighted the effectiveness of Synchrony-based IGRT in treating prostate cancer. This technology combines real-time imaging with precise radiation delivery, synchronizing with the prostate's natural movement to maintain accurate targeting and minimize damage to surrounding tissues. The treatment proved safe, precise, and facilitated quick recovery without side effects.

Both patients have expressed their gratitude to the medical team for their prompt intervention, allowing them to resume their daily routines without difficulties.

Dr. Gaurav Jaswal, MD Radiation Oncology, and Director of Radiation Oncology at Onco-Life Hospitals, stated that the AI-based Synchrony System represents a revolutionary advancement in cancer treatment. The hospital has obtained the necessary license from AERB for this technology, setting a new benchmark in cancer care with its state-of-the-art facilities and dedicated team of experts.

“At TGH-Onco-Life Cancer Centre, cutting-edge innovation meets compassionate care to provide cancer patients with the best possible treatment experience. This advanced technology allows for precise and customized treatment plans tailored to each patient’s needs,” Dr. Jaswal concluded.

Patients can now receive top-notch care that leverages the latest advancements in cancer treatment, ensuring better outcomes and improved quality of life.